Celgene Corporation (CELG) Shares Bought by Jackson Wealth Management LLC

Jackson Wealth Management LLC boosted its position in Celgene Corporation (NASDAQ:CELG) by 12.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 13,933 shares of the biopharmaceutical company’s stock after acquiring an additional 1,559 shares during the quarter. Jackson Wealth Management LLC’s holdings in Celgene Corporation were worth $1,884,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CELG. Neuberger Berman Group LLC grew its stake in shares of Celgene Corporation by 4.0% during the first quarter. Neuberger Berman Group LLC now owns 1,844,837 shares of the biopharmaceutical company’s stock valued at $229,553,000 after buying an additional 71,729 shares during the last quarter. Grisanti Capital Management LLC bought a new position in shares of Celgene Corporation during the second quarter valued at about $3,616,000. Lincoln Capital Corp grew its stake in shares of Celgene Corporation by 0.6% during the second quarter. Lincoln Capital Corp now owns 30,580 shares of the biopharmaceutical company’s stock valued at $3,971,000 after buying an additional 185 shares during the last quarter. RiverPoint Capital Management LLC grew its stake in shares of Celgene Corporation by 3.1% during the second quarter. RiverPoint Capital Management LLC now owns 121,654 shares of the biopharmaceutical company’s stock valued at $15,799,000 after buying an additional 3,680 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of Celgene Corporation by 9.2% during the second quarter. Russell Investments Group Ltd. now owns 641,697 shares of the biopharmaceutical company’s stock valued at $83,344,000 after buying an additional 54,210 shares during the last quarter. 79.16% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares of the company’s stock, valued at $564,768.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of Celgene Corporation stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Insiders have sold 20,227 shares of company stock valued at $2,843,956 in the last three months. 0.95% of the stock is owned by insiders.

A number of research analysts have recently issued reports on the company. Mizuho reaffirmed a “buy” rating on shares of Celgene Corporation in a research note on Friday, November 3rd. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and set a $166.00 price objective (up from $163.00) on shares of Celgene Corporation in a research note on Monday, October 30th. Cantor Fitzgerald reiterated a “hold” rating and set a $112.00 target price on shares of Celgene Corporation in a report on Monday, October 30th. J P Morgan Chase & Co set a $123.00 target price on shares of Celgene Corporation and gave the stock a “buy” rating in a report on Friday, October 27th. Finally, UBS AG dropped their target price on shares of Celgene Corporation from $146.00 to $120.00 and set a “buy” rating for the company in a report on Friday, October 27th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $139.64.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://transcriptdaily.com/2017/11/15/celgene-corporation-celg-shares-bought-by-jackson-wealth-management-llc.html.

Shares of Celgene Corporation (CELG) opened at $98.86 on Wednesday. The firm has a market cap of $79,644.98, a P/E ratio of 15.81, a P/E/G ratio of 0.78 and a beta of 1.79. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Corporation has a 1 year low of $94.55 and a 1 year high of $147.17.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.58 earnings per share. research analysts forecast that Celgene Corporation will post 6.67 EPS for the current fiscal year.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply